Completed PHASE2 INTERVENTIONAL NCT00034060

The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept

Suppression of the Growth Hormone/ Insulin-Like Growth Factor-1 (GH/IGF-1) Axis in Women With Rheumatoid Arthritis

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Interventions Etanercept

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Apr 30, 2002 Completion: Dec 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Healthy and Rheumatoid Arthritis, this trial is completed. The trial is conducted by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and has accumulated 5 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States